

# Ton Lisman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4073102/publications.pdf>

Version: 2024-02-01

365  
papers

15,956  
citations

15001

68  
h-index

27587

110  
g-index

400  
all docs

400  
docs citations

400  
times ranked

12045  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antithrombotic Management in Adult Kidney Transplantation: A European Survey Study. <i>European Surgical Research</i> , 2023, 64, 169-176.	0.6	1
2	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <i>Thrombosis and Haemostasis</i> , 2022, 122, 353-362.	1.8	7
3	Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus. <i>Hepatology</i> , 2022, 75, 898-911.	3.6	28
4	Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome. <i>Hepatology</i> , 2022, 75, 623-633.	3.6	25
5	Reply to: Correspondence on "Predicting portal thrombosis in cirrosis: A prospective study of clinical, ultrasonographic and hemostatic factors". <i>Journal of Hepatology</i> , 2022, 76, 227-228.	1.8	0
6	Reply. <i>Hepatology</i> , 2022, 75, 499-499.	3.6	0
7	Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 39-47.	1.9	39
8	Persistent endotheliopathy in the pathogenesis of long COVID syndrome: Comment from von Meijenfeldt et al.. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 267-269.	1.9	10
9	Long-term normothermic machine preservation of human livers: what is needed to succeed?. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 322, G183-G200.	1.6	10
10	Reply. <i>Hepatology</i> , 2022, 75, 770-771.	3.6	0
11	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	1.8	26
12	Effects of Inflammation on Hemostasis in Acutely Ill Patients with Liver Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 596-606.	1.5	7
13	EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 1151-1184.	1.8	112
14	Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates. <i>Liver International</i> , 2022, 42, 435-443.	1.9	8
15	Pathophysiology and management of bleeding and thrombosis in patients with liver disease. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 79-88.	0.7	4
16	Acquired bleeding disorders. <i>Haemophilia</i> , 2022, 28, 68-76.	1.0	7
17	Haemostatic alterations and management of haemostasis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 1291-1305.	1.8	33
18	Lower-leg injury and knee arthroscopy have distinct effects on coagulation. <i>Blood Advances</i> , 2022, 6, 5232-5243.	2.5	2

#	ARTICLE	IF	CITATIONS
19	The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2075-2082.	1.9	16
20	Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2306-2312.	1.9	6
21	On coagulation in advanced chronic liver disease and the origin of freshwater eels. <i>Journal of Hepatology</i> , 2022, 77, 886-887.	1.8	1
22	The international normalized ratio “Great for prediction of bleeding in patients taking vitamin K antagonists, useless for prediction of bleeding in patients with chronic liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1565-1567.	1.9	0
23	Unravelling the Role of Neutrophil Extracellular Traps in Acute Liver Failure. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, , .	2.3	0
24	Acquired bleeding disorders. <i>Haemophilia</i> , 2021, 27, 5-13.	1.0	9
25	VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure. <i>Hepatology</i> , 2021, 73, 1882-1891.	3.6	36
26	Global hemostatic status in patients with acute-on-chronic liver failure and sepsis without underlying liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 85-95.	1.9	38
27	Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality”Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 878-882.	1.1	157
28	Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 132-141.	1.0	69
29	Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 988-994.	1.1	146
30	Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 664-676.	1.9	29
31	Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 73, 366-413.	3.6	295
32	Transfusion with Cryoprecipitate for Very Low Fibrinogen Levels Does Not Affect Bleeding or Survival in Critically Ill Cirrhosis Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1317-1325.	1.8	23
33	Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. <i>Blood Advances</i> , 2021, 5, 756-759.	2.5	84
34	Controlled DCD Liver Transplantation Is not Associated With Increased Hyper-fibrinolysis and Blood Loss After Graft Reperfusion. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	0
35	Donor genetic variants as risk factors for thrombosis after liver transplantation: A genome-wide association study. <i>American Journal of Transplantation</i> , 2021, 21, 3133-3147.	2.6	4
36	COVID-19 is Associated with an Acquired Factor XIII Deficiency. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1668-1669.	1.8	15

#	ARTICLE	IF	CITATIONS
37	Hemostatic balance in acuteâ€”chronic liver failure. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 869-870.	1.9	1
38	The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1116-1122.	1.9	66
39	Fibrinolysis in Patients with Liver Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 601-609.	1.5	11
40	Major Thromboembolic Complications in Liver Transplantation: The Role of Rotational Thrombelastometry and Cryoprecipitate Transfusion. <i>Transplantation</i> , 2021, 105, e58-e59.	0.5	1
41	Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1472-1482.	1.9	3
42	Hemostatic and Nonhemostatic Effects of Heparan Sulfate Proteoglycans. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 238-239.	1.5	3
43	Histological Analysis of Donor Lung Derived Thrombi. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, S326-S327.	0.3	0
44	Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome. <i>Journal of Hepatology</i> , 2021, 74, 1264-1265.	1.8	6
45	Response by Mackman et al to Letter Regarding Article, "Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality" Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e381-e382.	1.1	7
46	Treatment of bleeding in patients with liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1644-1652.	1.9	16
47	Preface: Altered Fibrinolysis" Clinical Impact and Diagnostic Challenges. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 477-479.	1.5	3
48	Sustained prothrombotic changes in convalescent patients with COVID-19. <i>Lancet Haematology</i> , the, 2021, 8, e475.	2.2	5
49	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , 2021, 41, 2159-2170.	1.9	36
50	Aprotinin Inhibits Thrombin Generation by Inhibition of the Intrinsic Pathway, but is not a Direct Thrombin Inhibitor. <i>TH Open</i> , 2021, 05, e363-e375.	0.7	2
51	Tranexamic Acid Is Not a Universal Hemostatic Agent. <i>HemaSphere</i> , 2021, 5, e625.	1.2	3
52	Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. <i>Journal of Hepatology</i> , 2021, 75, 1367-1376.	1.8	73
53	Heparin " Messiah or Verschlimmbesserung?. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2373-2382.	1.9	8
54	Fresh frozen plasma in treating acute variceal bleeding: Not effective and likely harmful. <i>Liver International</i> , 2021, 41, 1710-1712.	1.9	2

#	ARTICLE	IF	CITATIONS
55	Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers. <i>Journal of Medical Virology</i> , 2021, 93, 5908-5916.	2.5	50
56	Dual Versus Single Oxygenated Hypothermic Machine Perfusion of Porcine Livers: Impact on Hepatobiliary and Endothelial Cell Injury. <i>Transplantation Direct</i> , 2021, 7, e741.	0.8	15
57	Therapeutic anticoagulation after liver transplantation is not useful among patients with pre-transplant Yerdel-grade I/II portal vein thrombosis: A two-center retrospective study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2760-2771.	1.9	2
58	Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure. <i>Hepatology</i> , 2021, 74, 937-949.	3.6	20
59	Aggravation of fibrin deposition and microthrombus formation within the graft during kidney transplantation. <i>Scientific Reports</i> , 2021, 11, 18937.	1.6	7
60	Elevated factor V activity and antigen levels in patients with Covid-19 are related to disease severity and 30-day mortality. <i>American Journal of Hematology</i> , 2021, 96, E98-E100.	2.0	6
61	Oxygen Transport during Ex Situ Machine Perfusion of Donor Livers Using Red Blood Cells or Artificial Oxygen Carriers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 235.	1.8	26
62	A high-dose 24-hour tranexamic acid infusion for the treatment of significant gastrointestinal bleeding: HALT-IT RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-86.	1.3	4
63	Fibrinolytic Shutdown in COVID-19 Is Likely a Misnomer. <i>Shock</i> , 2021, 55, 844-845.	1.0	4
64	Factor VIII/protein C ratio independently predicts liver-related events but does not reflect the hypercoagulable state in patients with advanced-chronic liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
65	Clinical Cirrhosis Dilemmas: Survey of Practice from the 7th International Coagulation in Liver Disease Conference. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1334-1339.	1.1	6
66	Von Willebrand factor delays liver repair after acetaminophen-induced acute liver injury in mice. <i>Journal of Hepatology</i> , 2020, 72, 146-155.	1.8	39
67	Nails in the coffin of fresh frozen plasma to prevent or treat bleeding in cirrhosis?. <i>Journal of Hepatology</i> , 2020, 72, 12-13.	1.8	12
68	Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute-on-Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival. <i>Hepatology</i> , 2020, 71, 1381-1390.	3.6	63
69	Evidence for a rebalanced hemostatic system in pediatric liver transplantation: A prospective cohort study. <i>American Journal of Transplantation</i> , 2020, 20, 1384-1392.	2.6	13
70	Reply. <i>Liver Transplantation</i> , 2020, 26, 604-605.	1.3	0
71	The Authors' Reply to Letter to the Editor, Re: Biliary Bicarbonate, pH, and Glucose Are Suitable Biomarkers of Biliary Viability During Ex Situ Normothermic Machine Perfusion of Human Donor Livers. <i>Transplantation</i> , 2020, 104, e41-e41.	0.5	0
72	In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2646-2653.	1.9	108

#	ARTICLE	IF	CITATIONS
73	Anticoagulant Management and Synthesis of Hemostatic Proteins during Machine Preservation of Livers for Transplantation. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 743-750.	1.5	6
74	Linkage analysis combined with whole-exome sequencing identifies a novel prothrombin ( <i>F2</i> ) gene mutation in a Dutch Caucasian family with unexplained thrombosis. <i>Haematologica</i> , 2020, 105, e370-e372.	1.7	6
75	Efficacy of pro- and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2840-2851.	1.9	8
76	Preanalytical variables affect thrombomodulin-modified thrombin generation in healthy volunteers. <i>Thrombosis Research</i> , 2020, 194, 237-239.	0.8	8
77	Pulmonary Megakaryocytes in Coronavirus Disease 2019 (COVID-19): Roles in Thrombosis and Fibrosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 831-834.	1.5	24
78	Blood Markers of Portal Hypertension Are Associated with Blood Loss and Transfusion Requirements during Orthotopic Liver Transplantation. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 751-756.	1.5	6
79	Metformin Preconditioning Improves Hepatobiliary Function and Reduces Injury in a Rat Model of Normothermic Machine Perfusion and Orthotopic Transplantation. <i>Transplantation</i> , 2020, 104, e271-e280.	0.5	12
80	The VWF/ADAMTS13 unbalance, but not global coagulation or fibrinolytic status, is associated with outcome and bleeding in patients with acute liver failure. <i>Journal of Hepatology</i> , 2020, 73, S24-S25.	1.8	5
81	Bleeding and Thrombosis in Patients with Liver Diseases. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 653-655.	1.5	3
82	Differentiating biochemical from clinical heparin resistance in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 1015-1016.	1.0	10
83	The Spectrum of Disease Severity in Cirrhosis and Its Implications for Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 716-723.	1.5	9
84	Thrombin Generation and Cirrhosis: State of the Art and Perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 693-703.	1.5	33
85	Global hemostatic status in patients with acute-on-chronic liver failure and patients with sepsis without underlying liver disease. <i>Journal of Hepatology</i> , 2020, 73, S496-S497.	1.8	0
86	A hypercoagulable state does not play a major role in the development of portal vein thrombosis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, S711-S712.	1.8	2
87	Author response to Letter to the Editor: "ABO, von Willebrand factor/Factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit?" <i>Liver International</i> , 2020, 40, 1790-1791.	1.9	3
88	Anticoagulant activity of edoxaban in patients with cirrhosis. <i>Blood</i> , 2020, 136, 1561-1564.	0.6	14
89	Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2020, 395, 1927-1936.	6.3	224
90	Extended hypothermic oxygenated machine perfusion enables ex situ preservation of porcine livers for up to 24 hours. <i>JHEP Reports</i> , 2020, 2, 100092.	2.6	34

#	ARTICLE	IF	CITATIONS
91	Interpreting Hemostatic Profiles Assessed With Viscoelastic Tests in Patients With Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 389-391.	1.1	27
92	Donor tobacco smoking is associated with postoperative thrombosis after primary liver transplantation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2590-2600.	1.9	4
93	In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1240-1247.	1.8	5
94	Hemostatic Changes of Acute Kidney Injury in Patients With Cirrhosis: What Do They Mean?. <i>Hepatology</i> , 2020, 72, 1163-1165.	3.6	1
95	Nanomedicine in Thrombosis and Hemostasis: The Future of Nanotechnology in Thrombosis and Hemostasis Research and Clinical Applications. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 521-523.	1.5	3
96	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1415-1426.	1.9	21
97	Routine Postoperative Antithrombotic Therapy in Pediatric Liver Transplantation: Impact on Bleeding and Thrombotic Complications. <i>Thrombosis and Haemostasis</i> , 2020, 120, 627-637.	1.8	7
98	Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 834-843.	1.9	22
99	INCREASED DEVELOPMENT OF MICROTHROMBI AND FIBRIN DEPOSITIONS IN DECEASED DONOR KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 2020, 104, S380-S380.	0.5	0
100	Plasma From Patients Undergoing Liver Transplantation Is Resistant to Anticoagulant Activity of Soluble Thrombomodulin. <i>Liver Transplantation</i> , 2019, 25, 252-259.	1.3	2
101	Perioperative hemostatic management in the cirrhotic patient: a position paper on behalf of the Liver Intensive Care Group of Europe (LICAGE). <i>Minerva Anestesiologica</i> , 2019, 85, 782-798.	0.6	46
102	Plasma levels of circulating DNA are associated with outcome, but not with activation of coagulation in decompensated cirrhosis and ACLF. <i>JHEP Reports</i> , 2019, 1, 179-187.	2.6	21
103	SAT-017-Anticoagulant effect of edoxaban in patients with cirrhosis: The POET study. <i>Journal of Hepatology</i> , 2019, 70, e632-e633.	1.8	1
104	Transplantation of high-risk donor livers after resuscitation and viability assessment using a combined protocol of oxygenated hypothermic, rewarming and normothermic machine perfusion: study protocol for a prospective, single-arm study (DHOPE-COR-NMP trial). <i>BMJ Open</i> , 2019, 9, e028596.	0.8	26
105	Intrahepatic fibrin(ogen) deposition drives liver regeneration after partial hepatectomy in mice and humans. <i>Blood</i> , 2019, 133, 1245-1256.	0.6	46
106	Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 246-253.	1.8	52
107	Decreased Fibrinolytic Capacity in Cirrhosis and Liver Transplantation Outcomes. <i>Liver Transplantation</i> , 2019, 25, 359-361.	1.3	6
108	SAT-077-Intraperitoneal activation of blood coagulation via tissue factor-exposing extracellular vesicles in patients with advanced chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e661.	1.8	0

#	ARTICLE	IF	CITATIONS
109	Biliary Bicarbonate, pH, and Glucose Are Suitable Biomarkers of Biliary Viability During Ex Situ Normothermic Machine Perfusion of Human Donor Livers. <i>Transplantation</i> , 2019, 103, 1405-1413.	0.5	133
110	Evaluation of hemostasis in patients with end-stage renal disease. <i>PLoS ONE</i> , 2019, 14, e0212237.	1.1	43
111	Transplantation of High-risk Donor Livers After Ex Situ Resuscitation and Assessment Using Combined Hypo- and Normothermic Machine Perfusion. <i>Annals of Surgery</i> , 2019, 270, 906-914.	2.1	161
112	Crosslinked clots formed independently of factor XIII and without fibrinogen-to-fibrin conversion "is this a liver-specific phenomenon?". <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 110-112.	1.9	1
113	Chronic liver injury drives non-traditional intrahepatic fibrin(ogen) crosslinking via tissue transglutaminase. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 113-125.	1.9	21
114	Reply. <i>Liver Transplantation</i> , 2019, 25, 182-183.	1.3	0
115	Perioperative antithrombotic therapy does not increase the incidence of early postoperative thromboembolic complications and bleeding in kidney transplantation "a retrospective study. <i>Transplant International</i> , 2019, 32, 418-430.	0.8	10
116	Peribiliary Glands Are Key in Regeneration of the Human Biliary Epithelium After Severe Bile Duct Injury. <i>Hepatology</i> , 2019, 69, 1719-1734.	3.6	44
117	Understanding and Managing the Coagulopathy of Liver Disease. , 2019, , 734-746.		0
118	The impact of ABO blood type on VWF and factor VIII levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.2	0
119	Intraperitoneal activation of the coagulation system via tissue factor-exposing extracellular vesicles and enhanced fibrinolysis in patients with advanced chronic liver disease and ascites. , 2019, 57, .		0
120	Removal of destructive brain-borne microdust. <i>Blood</i> , 2018, 131, 477-478.	0.6	0
121	Extrahemostatic Functions of Platelets and Coagulation Factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 089-090.	1.5	11
122	Mechanisms of enhanced thrombin-generating capacity in patients with cirrhosis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1128-1131.	1.9	24
123	Fibrin fuels fatty liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 3-5.	1.9	9
124	Normothermic machine perfusion of donor livers without the need for human blood products. <i>Liver Transplantation</i> , 2018, 24, 528-538.	1.3	81
125	Systematic comparison of routine laboratory measurements with in-hospital mortality: ICU-Labome, a large cohort study of critically ill patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1140-1151.	1.4	5
126	Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 152-160.	1.8	15

#	ARTICLE	IF	CITATIONS
127	Platelet-leucocyte aggregation is augmented in cirrhosis and further increased by platelet transfusion. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1375-1386.	1.9	17
128	Comment to "Antithrombin III administration for portal vein thrombosis in patients with liver disease: A randomized double-blind controlled trial". <i>Hepatology Research</i> , 2018, 48, E379-E380.	1.8	1
129	Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. <i>Journal of Critical Care</i> , 2018, 43, 54-60.	1.0	87
130	Platelets as Modulators of Liver Diseases. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 114-125.	1.5	46
131	Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease. <i>Cell and Tissue Research</i> , 2018, 371, 567-576.	1.5	159
132	Repopulating the biliary tree from the peribiliary glands. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1524-1531.	1.8	30
133	Hemostasis and Thrombosis in Extreme Physiological and Pathological Conditions. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 615-616.	1.5	4
134	Three strikes to a hemophilic joint bleed. <i>Blood</i> , 2018, 132, 1548-1550.	0.6	1
135	Elevated Plasma Levels of Cell-Free DNA During Liver Transplantation Are Associated With Activation of Coagulation. <i>Liver Transplantation</i> , 2018, 24, 1716-1725.	1.3	34
136	In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis. <i>Liver International</i> , 2018, 38, 1988-1996.	1.9	35
137	Physiology, Prevention, and Treatment of Blood Loss During Liver Transplantation. , 2018, , 195-206.		0
138	Preemptively and non-preemptively transplanted patients show a comparable hypercoagulable state prior to kidney transplantation compared to living kidney donors. <i>PLoS ONE</i> , 2018, 13, e0200537.	1.1	10
139	Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2018, 38, 2210-2218.	1.9	39
140	Production of Physiologically Relevant Quantities of Hemostatic Proteins During Ex Situ Normothermic Machine Perfusion of Human Livers. <i>Liver Transplantation</i> , 2018, 24, 1298-1302.	1.3	15
141	Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease. <i>Thrombosis Research</i> , 2017, 150, 41-43.	0.8	5
142	In vitro uptake of recombinant factor VIIa by megakaryocytes with subsequent production of platelets containing functionally active drug. <i>British Journal of Haematology</i> , 2017, 178, 482-486.	1.2	4
143	Hemostatic issues in pregnancy-induced liver disease. <i>Thrombosis Research</i> , 2017, 151, S78-S81.	0.8	8
144	Transient von Willebrand factor-mediated platelet influx stimulates liver regeneration after partial hepatectomy in mice. <i>Liver International</i> , 2017, 37, 1731-1737.	1.9	39

#	ARTICLE	IF	CITATIONS
145	Fibrinolysis: Biochemistry, Clinical Aspects, and Therapeutic Potential. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 113-114.	1.5	17
146	Oxygenated hypothermic machine perfusion after static cold storage improves endothelial function of extended criteria donor livers. <i>Hpb</i> , 2017, 19, 538-546.	0.1	39
147	Dual hypothermic oxygenated machine perfusion in liver transplants donated after circulatory death. <i>British Journal of Surgery</i> , 2017, 104, 907-917.	0.1	201
148	Management of Hemostatic Disorders in Patients With Advanced Liver Disease Admitted to an Intensive Care Unit. <i>Transfusion Medicine Reviews</i> , 2017, 31, 245-251.	0.9	14
149	Von Willebrand factor deficiency reduces liver fibrosis in mice. <i>Toxicology and Applied Pharmacology</i> , 2017, 328, 54-59.	1.3	16
150	Hemostatic and Non-hemostatic Functions of Platelets in Patients with Liver Disease. , 2017, , 1169-1181.		2
151	Value of Preoperative Hemostasis Testing in Patients with Liver Disease for Perioperative Hemostatic Management. <i>Anesthesiology</i> , 2017, 126, 338-344.	1.3	45
152	Global assays of fibrinolysis. <i>International Journal of Laboratory Hematology</i> , 2017, 39, e140-e141.	0.7	1
153	Activation of Fibrinolysis, But Not Coagulation, During End-Ischemic Ex Situ Normothermic Machine Perfusion of Human Donor Livers. <i>Transplantation</i> , 2017, 101, e42-e48.	0.5	27
154	Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 150-161.	1.0	92
155	Response to cautious use of platelet as relevant inducer of liver regeneration following partial hepatectomy in patients with metastatic hepatic carcinoma. <i>Liver International</i> , 2017, 37, 1918-1919.	1.9	0
156	Hemostatic Complications in Hepatobiliary Surgery. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 732-741.	1.5	9
157	The cirrhotic platelet: Shedding light on an enigma. <i>Hepatology</i> , 2017, 65, 407-410.	3.6	17
158	Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 178-184.	1.5	48
159	Assessing in vivo platelet activation in patients with liver diseases. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 52-53.	1.0	2
160	Re: Bleeding Risk and Management in Interventional Procedures in Chronic Liver Disease. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1336-1337.	0.2	2
161	Response to the role of platelets on regenerating liver: Thoughts beyond parenchymal proliferation. <i>Liver International</i> , 2017, 37, 1917-1917.	1.9	0
162	Thromboelastography does not predict outcome in different etiologies of cirrhosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 275-285.	1.0	31

#	ARTICLE	IF	CITATIONS
163	Cirrhosis as a risk factor for venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2017, 117, 03-05.	1.8	24
164	Reply to: "Procoagulant imbalance in patients with non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , 2017, 66, 250-251.	1.8	13
165	Normothermic machine perfusion reduces bile duct injury and improves biliary epithelial function in rat donor livers. <i>Liver Transplantation</i> , 2016, 22, 994-1005.	1.3	58
166	Role of hemostatic factors in hepatic injury and disease: animal models de liver. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1337-1349.	1.9	38
167	Alterations in Fibrin Structure in Patients with Liver Diseases. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 389-396.	1.5	59
168	Fibrin fixes fibrosis. <i>Blood</i> , 2016, 127, 2662-2664.	0.6	1
169	Mechanisms of platelet-mediated liver regeneration. <i>Blood</i> , 2016, 128, 625-629.	0.6	56
170	Balance between von Willebrand factor and ADAMTS13 following major partial hepatectomy. <i>British Journal of Surgery</i> , 2016, 103, 735-743.	0.1	21
171	Preserved hemostatic status in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 65, 980-987.	1.8	72
172	Oxygenated Hypothermic Machine Perfusion After Static Cold Storage Improves Hepatobiliary Function of Extended Criteria Donor Livers. <i>Transplantation</i> , 2016, 100, 825-835.	0.5	94
173	Normothermic machine perfusion of donor livers using a novel hemoglobin based oxygen carrier solution, eliminating the need for human blood products. <i>Hpb</i> , 2016, 18, e73.	0.1	1
174	The Role of Fibrinogen and Factor XIII in Hemostasis, and the Identification and Treatment of Associated Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 331-332.	1.5	6
175	Prediction of bleeding in cirrhosis patients: Is the forecast any clearer?. <i>Hepatology</i> , 2016, 64, 989-990.	3.6	20
176	Plasma molecules predicting liver dysfunction following partial hepatectomy are not only derived from platelet $\alpha$ granules. <i>Hepatology</i> , 2016, 64, 991-992.	3.6	3
177	Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1054-1066.	1.9	102
178	Thrombocytopenia Is Associated With Multi-organ System Failure in Patients With Acute Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 613-620.e4.	2.4	70
179	A sustained decrease in plasma fibrinolytic potential following partial liver resection or pancreas resection. <i>Thrombosis Research</i> , 2016, 140, 36-40.	0.8	9
180	Evidence against a role for platelet-derived molecules in liver regeneration after partial hepatectomy in humans. <i>Journal of Clinical and Translational Research</i> , 2016, 2, 97-106.	0.3	1

#	ARTICLE	IF	CITATIONS
181	Diffuse reflectance spectroscopy accurately quantifies various degrees of liver steatosis in murine models of fatty liver disease. <i>Journal of Translational Medicine</i> , 2015, 13, 309.	1.8	14
182	Coagulation activation during air travel is not initiated via the extrinsic pathway. <i>British Journal of Haematology</i> , 2015, 169, 903-905.	1.2	4
183	Horizontal RNA transfer mediates platelet-induced hepatocyte proliferation. <i>Blood</i> , 2015, 126, 798-806.	0.6	72
184	Ex Situ Normothermic Machine Perfusion of Donor Livers. <i>Journal of Visualized Experiments</i> , 2015, , e52688.	0.2	17
185	Thrombolytic protocol minimizes ischemic-type biliary complications in liver transplantation from donation after circulatory death donors. <i>Liver Transplantation</i> , 2015, 21, 1231-1232.	1.3	9
186	Decreased plasma levels of activated factor VII in patients with deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1320-1324.	1.9	4
187	End-ischemic machine perfusion reduces bile duct injury in donation after circulatory death rat donor livers independent of the machine perfusion temperature. <i>Liver Transplantation</i> , 2015, 21, 1300-1311.	1.3	56
188	Ex vivo addition of fibrinogen concentrate improves the fibrin network structure in plasma samples taken during liver transplantation. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2192-2201.	1.9	22
189	Vitamin E Attenuates the Progression of Non-Alcoholic Fatty Liver Disease Caused by Partial Hepatectomy in Mice. <i>PLoS ONE</i> , 2015, 10, e0143121.	1.1	17
190	Letter by Hugenholtz and Lisman Regarding Article, "Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy" <i>Circulation</i> , 2015, 131, e18.	1.6	7
191	The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa. <i>Blood Reviews</i> , 2015, 29, 223-229.	2.8	11
192	The role of platelets in liver regeneration "What don't we know?". <i>Journal of Hepatology</i> , 2015, 63, 1537-1538.	1.8	12
193	Evidence against a role of serotonin in liver regeneration in humans. <i>Hepatology</i> , 2015, 62, 983-983.	3.6	13
194	Management of coagulation abnormalities in liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 103-114.	1.4	16
195	Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis. <i>Liver International</i> , 2015, 35, 1809-1815.	1.9	32
196	No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. <i>Thrombosis Research</i> , 2015, 135, 292-297.	0.8	23
197	Hypercoagulability following major partial liver resection -detected by thrombomodulin-modified thrombin generation testing. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 189-198.	1.9	32
198	Development of a Hyperactive Primary Hemostatic System During Off-Pump Lung Transplantation Resulting From an Unbalance Between von Willebrand Factor and Its Cleaving Protease ADAMTS13. <i>American Journal of Transplantation</i> , 2015, 15, 1958-1966.	2.6	3

#	ARTICLE	IF	CITATIONS
199	Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. <i>Hepatology</i> , 2015, 61, 1435-1436.	3.6	49
200	Issues With Monitoring of Unfractionated Heparin in Cirrhosis. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 279-280.	1.0	6
201	Preserved clot formation detected by the Thrombodynamics analyzer in patients with cirrhosis. <i>Thrombosis Research</i> , 2015, 135, 1012-1016.	0.8	14
202	Hemostatic Dysfunction in Liver Diseases. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 445-446.	1.5	19
203	Rebalanced Hemostasis in Patients with Acute Liver Failure. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 468-473.	1.5	86
204	Coagulation-driven platelet activation reduces cholestatic liver injury and fibrosis in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 57-71.	1.9	45
205	Platelets and fibrin in progression of liver disease: friends or foes?. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 54-56.	1.9	18
206	Development of a Hypercoagulable Status in Patients Undergoing Off-Pump Lung Transplantation despite Prolonged Conventional Coagulation Tests. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 230-233.	2.5	10
207	Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?. <i>Blood Reviews</i> , 2015, 29, 127-136.	2.8	36
208	Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma. <i>Platelets</i> , 2015, 26, 577-582.	1.1	14
209	Liver Transplantation in Groningen, The Netherlands: A Single Center Status Report. <i>Clinical Transplants</i> , 2015, 31, 101-111.	0.2	0
210	Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e88390.	1.1	79
211	Hypothermic Oxygenated Machine Perfusion Prevents Arteriolonecrosis of the Peribiliary Plexus in Pig Livers Donated after Circulatory Death. <i>PLoS ONE</i> , 2014, 9, e88521.	1.1	103
212	Injury to Peribiliary Glands and Vascular Plexus Before Liver Transplantation Predicts Formation of Non-Anastomotic Biliary Strictures.. <i>Transplantation</i> , 2014, 98, 175.	0.5	1
213	Injury of Peribiliary Glands and Vascular Plexus Before Liver Transplantation Predicts Formation of Non-Anastomotic Biliary Strictures.. <i>Transplantation</i> , 2014, 98, 342.	0.5	0
214	No increased systemic fibrinolysis in women with heavy menstrual bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1488-1493.	1.9	12
215	Injury to peribiliary glands and vascular plexus before liver transplantation predicts formation of non-anastomotic biliary strictures. <i>Journal of Hepatology</i> , 2014, 60, 1172-1179.	1.8	170
216	Duct-to-duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy. <i>Liver Transplantation</i> , 2014, 20, 457-463.	1.3	41

#	ARTICLE	IF	CITATIONS
217	Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. <i>Liver International</i> , 2014, 34, 26-32.	1.9	89
218	Hemostasis in Liver Disease: Implications of New Concepts for Perioperative Management. <i>Transfusion Medicine Reviews</i> , 2014, 28, 107-113.	0.9	108
219	Thrombomodulin-modified thrombin generation testing detects a hypercoagulable state in patients with cirrhosis regardless of the exact experimental conditions. <i>Thrombosis Research</i> , 2014, 134, 753-756.	0.8	39
220	Low molecular weight heparin in management and prevention of portal vein thrombosis. <i>Thrombosis Research</i> , 2014, 134, 761-762.	0.8	5
221	Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans. <i>Thrombosis and Haemostasis</i> , 2014, 112, 304-310.	1.8	6
222	Infusion of DDAVP Does Not Improve Primary Hemostasis in Patients with Cirrhosis. <i>Blood</i> , 2014, 124, 5044-5044.	0.6	1
223	Early elevated serum gamma glutamyl transpeptidase after liver transplantation is associated with better survival. <i>F1000Research</i> , 2014, 3, 85.	0.8	10
224	Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation. <i>F1000Research</i> , 2014, 3, 103.	0.8	6
225	Criteria for Viability Assessment of Discarded Human Donor Livers during Ex Vivo Normothermic Machine Perfusion. <i>PLoS ONE</i> , 2014, 9, e110642.	1.1	156
226	Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial. <i>BMC Surgery</i> , 2013, 13, 22.	0.6	65
227	Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient. <i>Liver International</i> , 2013, 33, 820-827.	1.9	68
228	Established and new-generation antithrombotic drugs in patients with cirrhosis – Possibilities and caveats. <i>Journal of Hepatology</i> , 2013, 59, 358-366.	1.8	107
229	Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels. <i>British Journal of Haematology</i> , 2013, 162, 819-826.	1.2	14
230	Ex vivo Normothermic Machine Perfusion and Viability Testing of Discarded Human Donor Livers. <i>American Journal of Transplantation</i> , 2013, 13, 1327-1335.	2.6	243
231	An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome. <i>Hepatology</i> , 2013, 58, 752-761.	3.6	153
232	Increased mortality in systemic inflammatory response syndrome patients with high levels of coagulation factor VIIa. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 2111-2117.	1.9	17
233	<i>In vitro</i> effects of proteases in human pancreatic juice on stability of liquid and carrier-bound fibrin sealants. <i>British Journal of Surgery</i> , 2013, 100, 1498-1504.	0.1	9
234	The impact of hepatic steatosis on liver regeneration after partial hepatectomy. <i>Liver International</i> , 2013, 33, 469-475.	1.9	42

#	ARTICLE	IF	CITATIONS
235	Routine coagulation assays underestimate levels of antithrombinâ€dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. <i>British Journal of Haematology</i> , 2013, 163, 666-673.	1.2	69
236	TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation. <i>Thrombosis and Haemostasis</i> , 2013, 109, 948-955.	1.8	19
237	Understanding and Managing the Coagulopathy of Liver Disease. , 2013, , 688-697.		0
238	Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia. <i>New England Journal of Medicine</i> , 2012, 367, 2055-2056.	13.9	15
239	Prohemostatic Interventions in Liver Surgery. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 244-249.	1.5	28
240	Role of Fibrin Sealants in Liver Surgery. <i>Digestive Surgery</i> , 2012, 29, 54-61.	0.6	50
241	Fibrinolytic Proteins in Human Bile Accelerate Lysis of Plasma Clots and Induce Breakdown of Fibrin Sealants. <i>Annals of Surgery</i> , 2012, 256, 306-312.	2.1	25
242	The circulating platelet count is not dictated by the liver, but may be determined in part by the bone marrow: analyses from human liver and stem cell transplantations. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1624-1630.	1.9	5
243	Physiology, Prevention, and Treatment of Blood Loss During Liver Transplantation. , 2012, , 169-179.		1
244	Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1312-1319.	1.9	101
245	Bivalirudin is inferior to heparin in preservation of intraoperative autologous blood. <i>Thrombosis Research</i> , 2012, 130, 163-165.	0.8	16
246	Regeneration of human extrahepatic biliary epithelium: the peribiliary glands as progenitor cell compartment. <i>Liver International</i> , 2012, 32, 554-559.	1.9	54
247	Pitfalls in assessing platelet activation status in patients with liver disease. <i>Liver International</i> , 2012, 32, 1027-1027.	1.9	10
248	Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. <i>Journal of Hepatology</i> , 2012, 56, 129-136.	1.8	241
249	Platelet function in patients with cirrhosis. <i>Journal of Hepatology</i> , 2012, 56, 993-994.	1.8	21
250	Platelet Function in Stored Heparinised Autologous Blood Is Not Superior to in Patient Platelet Function during Routine Cardiopulmonary Bypass. <i>PLoS ONE</i> , 2012, 7, e33686.	1.1	7
251	Early hepatic regeneration index and completeness of regeneration at 6 months after partial hepatectomy. <i>British Journal of Surgery</i> , 2012, 99, 1113-1119.	0.1	37
252	Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO caseâ€control study. <i>British Journal of Haematology</i> , 2012, 156, 252-258.	1.2	18

#	ARTICLE	IF	CITATIONS
253	Plasma levels of Midkine (neurite growth-promoting factor 2) are not associated with plasma fibrinolytic potential or risk of venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 964-966.	1.9	0
254	Beneficial effects of gaseous hydrogen sulfide in hepatic ischemia/reperfusion injury. <i>Transplant International</i> , 2012, 25, 897-908.	0.8	29
255	Recombinant factor VIIa to treat severe bleeding in patients with liver disease: Pitfalls and possibilities. <i>Journal of Hepatology</i> , 2011, 55, 950-951.	1.8	3
256	Anemia as a potential contributor to bleeding in patients with liver disease – “Neglected but not forgotten”. <i>Journal of Hepatology</i> , 2011, 54, 594-595.	1.8	11
257	Prothrombotic Gene Polymorphisms: Possible Contributors to Hepatic Artery Thrombosis After Orthotopic Liver Transplantation. <i>Transplantation</i> , 2011, 92, 587-593.	0.5	16
258	Protection of Bile Ducts in Liver Transplantation: Looking Beyond Ischemia. <i>Transplantation</i> , 2011, 92, 373-379.	0.5	100
259	The hemostatic status of pediatric recipients of adult liver grafts suggests that plasma levels of hemostatic proteins are not regulated by the liver. <i>Blood</i> , 2011, 117, 2070-2072.	0.6	22
260	Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction. <i>Blood</i> , 2011, 117, 6694-6701.	0.6	19
261	Genome scan of clot lysis time and its association with thrombosis in a protein-deficient kindred. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1383-1390.	1.9	4
262	Activation of hemostasis in brain dead organ donors: an observational study. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1959-1965.	1.9	23
263	The combination of primary sclerosing cholangitis and CCR5 <sup>Δ32</sup> in recipients is strongly associated with the development of nonanastomotic biliary strictures after liver transplantation. <i>Liver International</i> , 2011, 31, 1102-1109.	1.9	23
264	Towards a rational use of low-molecular-weight heparin in patients with cirrhosis. <i>Liver International</i> , 2011, 31, 1063-1063.	1.9	33
265	Hepatic Artery Diseases. <i>Molecular Pathology Library</i> , 2011, , 701-708.	0.1	0
266	Platelets Play an Important Role in the Recovery of Liver Dysfunction After Hepatic Resection. <i>Annals of Surgery</i> , 2010, 252, 709.	2.1	0
267	Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. <i>Blood</i> , 2010, 116, 529-536.	0.6	73
268	Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. <i>Blood</i> , 2010, 116, 113-121.	0.6	309
269	Activation of Coagulation by Living Donor Kidney Transplants Early After Reperfusion. <i>American Journal of Transplantation</i> , 2010, 10, 434-434.	2.6	2
270	The International Normalized Ratio (INR) in the MELD Score: Problems and Solutions. <i>American Journal of Transplantation</i> , 2010, 10, 1349-1353.	2.6	75

#	ARTICLE	IF	CITATIONS
271	Hypofibrinolysis as a risk factor for recurrent venous thrombosis; results of the LETS follow-up study. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 605-607.	1.9	28
272	Reporting prothrombin time results as international normalized ratios for patients with chronic liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1410-1412.	1.9	30
273	Intact thrombomodulin-mediated regulation of fibrinolysis during and after liver transplantation, despite a profoundly defective thrombomodulin-mediated regulation of coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1646-1649.	1.9	12
274	Transmission of idiopathic thrombocytopenic purpura during orthotopic liver transplantation. <i>Transplant International</i> , 2010, 23, 236-238.	0.8	17
275	Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1181-1187.	1.8	40
276	Immediate Postoperative Low Platelet Count is Associated With Delayed Liver Function Recovery After Partial Liver Resection. <i>Annals of Surgery</i> , 2010, 251, 300-306.	2.1	106
277	Activation and Regulation of Hemostasis in Acute Liver Failure and Acute Pancreatitis. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 437-443.	1.5	29
278	The Role of Platelets in Liver Inflammation and Regeneration. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 170-174.	1.5	54
279	Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. <i>Journal of Hepatology</i> , 2010, 52, 355-361.	1.8	191
280	The interaction of recombinant factor VIIa with platelet glycoprotein Ib. <i>Thrombosis Research</i> , 2010, 125, S13-S15.	0.8	6
281	Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. <i>Blood</i> , 2010, 116, 878-885.	0.6	536
282	Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. <i>Thrombosis and Haemostasis</i> , 2009, 101, 465-470.	1.8	30
283	Factor XI Binding to Platelets. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1409-1410.	1.1	3
284	Inflammation Mediated Down-Regulation of Hepatobiliary Transporters Contributes to Intrahepatic Cholestasis and Liver Damage in Murine Biliary Atresia. <i>Pediatric Research</i> , 2009, 66, 380-385.	1.1	13
285	The Impact of the Fibrinolytic System on the Risk of Venous and Arterial Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 468-477.	1.5	65
286	Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. <i>Haematologica</i> , 2009, 94, 811-818.	1.7	42
287	Development of a Severe von Willebrand Factor/ADAMTS13 Dysbalance During Orthotopic Liver Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 1189-1196.	2.6	78
288	No evidence for systemic platelet activation during or after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 956-962.	1.3	12

#	ARTICLE	IF	CITATIONS
289	Hypofibrinolysis is a risk factor for arterial thrombosis at young age. <i>British Journal of Haematology</i> , 2009, 145, 115-120.	1.2	74
290	Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. <i>British Journal of Haematology</i> , 2009, 145, 121-127.	1.2	62
291	Hepatic artery thrombosis after liver transplantation: more than just a surgical complication?. <i>Transplant International</i> , 2009, 22, 162-164.	0.8	30
292	Staphylococcal superantigen $\alpha$ 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ib $\alpha$ and $\beta$ 3. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1867-1874.	1.9	53
293	How to minimize blood loss during liver surgery in patients with cirrhosis. <i>Hpb</i> , 2009, 11, 453-458.	0.1	38
294	Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy?. <i>Hpb</i> , 2009, 11, 459-464.	0.1	63
295	Bleeding in Liver Surgery: Prevention and Treatment. <i>Clinics in Liver Disease</i> , 2009, 13, 145-154.	1.0	92
296	The Platelet and Platelet Function Testing in Liver Disease. <i>Clinics in Liver Disease</i> , 2009, 13, 11-20.	1.0	55
297	Effects of acidosis, alkalosis, hyperthermia and hypothermia on haemostasis: results of point of care testing with the thromboelastography analyser. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 436-439.	0.5	45
298	Platelet Transfusion During Liver Transplantation Is Associated with Increased Postoperative Mortality Due to Acute Lung Injury. <i>Anesthesia and Analgesia</i> , 2009, 108, 1083-1091.	1.1	198
299	Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. <i>Thrombosis and Haemostasis</i> , 2009, 101, 465-70.	1.8	6
300	Hemostasis in patients with liver disease. <i>Acta Gastro-Enterologica Belgica</i> , 2009, 72, 433-40.	0.4	3
301	Platelets in liver transplantation: Friend or foe?. <i>Liver Transplantation</i> , 2008, 14, 923-931.	1.3	92
302	Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. <i>Leukemia Research</i> , 2008, 32, 1078-1084.	0.4	65
303	Interlaboratory variability in assessment of the model of end-stage liver disease score. <i>Liver International</i> , 2008, 28, 1344-1351.	1.9	71
304	A heparin-bonded vascular graft generates no systemic effect on markers of hemostasis activation or detectable heparin-induced thrombocytopenia-associated antibodies in humans. <i>Journal of Vascular Surgery</i> , 2008, 47, 324-329.	0.6	33
305	The influence of the pulsatility of the blood flow on the extent of platelet adhesion. <i>Thrombosis Research</i> , 2008, 121, 821-825.	0.8	17
306	Salvianolic Acid B inhibits platelet adhesion under conditions of flow by a mechanism involving the collagen receptor $\alpha$ 2b1. <i>Thrombosis Research</i> , 2008, 123, 298-305.	0.8	44

#	ARTICLE	IF	CITATIONS
307	Tissue Factor-independent Effects of Recombinant Factor VIIa on Hemostasis. <i>Seminars in Hematology</i> , 2008, 45, S12-S15.	1.8	12
308	Cell-collagen interactions: the use of peptide Toolkits to investigate collagen-receptor interactions. <i>Biochemical Society Transactions</i> , 2008, 36, 241-250.	1.6	170
309	Mechanisms of the Factor V Leiden Paradox. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1872-1877.	1.1	47
310	The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. <i>Blood</i> , 2008, 112, 3227-3233.	0.6	69
311	The two tales of coagulation in liver transplantation. <i>Current Opinion in Organ Transplantation</i> , 2008, 13, 298-303.	0.8	69
312	Synergistic Effects of Hypofibrinolysis and Genetic and Acquired Risk Factors on the Risk of a First Venous Thrombosis. <i>PLoS Medicine</i> , 2008, 5, e97.	3.9	96
313	Staphylococcal Superantigen-Like 5 Activates Platelets, and Supports Platelet Adhesion Under Flow Conditions, Which Is Mediated by GPIb-Alpha and Alpha-IIb-Beta-3. <i>Blood</i> , 2008, 112, 3922-3922.	0.6	0
314	Platelet Activation by Oxidized Low Density Lipoprotein Is Mediated by Cd36 and Scavenger Receptor-A. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2476-2483.	1.1	87
315	Hemostatic Alterations in Liver Disease: A Review on Pathophysiology, Clinical Consequences, and Treatment. <i>Digestive Surgery</i> , 2007, 24, 250-258.	0.6	155
316	Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. <i>Blood</i> , 2007, 109, 2430-2437.	0.6	61
317	Fibrinolysis and the risk of venous and arterial thrombosis. <i>Current Opinion in Hematology</i> , 2007, 14, 242-248.	1.2	35
318	Antiplatelet medication after liver transplantation: Does it affect outcome?. <i>Liver Transplantation</i> , 2007, 13, 644-646.	1.3	17
319	Platelet adhesion to dimeric Î²2-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ib and apolipoprotein E receptor 2. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 369-377.	1.9	106
320	A mechanism to safeguard platelet adhesion under high-shear flow: von Willebrand factor-glycoprotein Ib and integrin Î±2Î²1-collagen interactions make complementary, collagen-type-specific contributions to adhesion: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1338-1339.	1.9	1
321	GLYCOPROTEIN IB-ALPHA CONTRIBUTES TO TISSUE FACTOR-INDEPENDENT THROMBIN GENERATION BY RECOMBINANT FACTOR VIIA ON THE ACTIVATED PLATELET SURFACE. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, O-S-042-O-S-042.	1.9	2
322	Heparin immobilization reduces thrombogenicity of small-caliber expanded polytetrafluoroethylene grafts. <i>Journal of Vascular Surgery</i> , 2006, 43, 587-591.	0.6	73
323	Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients. <i>Thrombosis and Haemostasis</i> , 2006, 96, 100-101.	1.8	49
324	A single high-affinity binding site for von Willebrand factor in collagen III, identified using synthetic triple-helical peptides. <i>Blood</i> , 2006, 108, 3753-3756.	0.6	112

#	ARTICLE	IF	CITATIONS
325	Hemostasis in chronic liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2059-2060.	1.9	27
326	Hemostasis in chronic liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2061-2062.	1.9	16
327	Hemostasis in chronic liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2062-2063.	1.9	14
328	No evidence for an intrinsic platelet defect in patients with liver cirrhosis “ studies under flow conditions. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2070-2072.	1.9	60
329	The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. <i>British Journal of Haematology</i> , 2006, 134, 92-94.	1.2	49
330	Severe Prolongation of the INR in Spur Cell Anemia of Cirrhosis: True-True and Related?. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1203-1205.	1.1	8
331	Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. <i>Hepatology</i> , 2006, 44, 53-61.	3.6	534
332	Glycoprotein Ib $\alpha$ -Mediated Platelet Adhesion and Aggregation to Immobilized Thrombin Under Conditions of Flow. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 670-675.	1.1	27
333	Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. <i>Journal of Experimental Medicine</i> , 2006, 203, 1419-1425.	4.2	278
334	ID: 199 Binding of TAFI to collagen: a role for TAFI in the regulation of platelet adhesion?. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 208-208.	1.9	1
335	O-Linked Glycosylation with Sialylated T-Antigen: A Novel Carbohydrate Determinant of von Willebrand Factor Antigen Levels.. <i>Blood</i> , 2006, 108, 178-178.	0.6	4
336	Hypofibrinolysis as a Risk Factor for Venous Thrombosis.. <i>Blood</i> , 2006, 108, 272-272.	0.6	2
337	Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. <i>Blood</i> , 2005, 105, 1102-1105.	0.6	246
338	Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 742-751.	1.9	83
339	Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1993-1997.	1.9	183
340	Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1341-1343.	1.8	37
341	Platelet aggregation: involvement of thrombin and fibrin(ogen). <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2504.	3.0	51
342	Identification of the von Willebrand Factor Binding Site in Collagen Using Triple Helical Peptides.. <i>Blood</i> , 2005, 106, 413-413.	0.6	0

#	ARTICLE	IF	CITATIONS
343	Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy. <i>Biomedical and Environmental Sciences</i> , 2005, 18, 260-4.	0.2	24
344	Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1341-3.	1.8	8
345	Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. <i>Translational Research</i> , 2004, 144, 100-107.	2.4	13
346	Circulating endothelial cells in cancer patients do not express tissue factor. <i>Cancer Letters</i> , 2004, 213, 241-248.	3.2	23
347	Recombinant factor VIIa restores aggregation of $\beta_3$ -deficient platelets via tissue factor-independent fibrin generation. <i>Blood</i> , 2004, 103, 1720-1727.	0.6	76
348	Recombinant Factor VIIa Enhances Platelet Adhesion and Aggregation under Flow Conditions at Normal and Reduced Platelet Count.. <i>Blood</i> , 2004, 104, 2618-2618.	0.6	0
349	Mechanism of Action of Recombinant Activated Factor VII. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2003, 5, 5-10.	0.2	2
350	Rebuttal to: Effect of heparin on TAFI-dependent inhibition of fibrinolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 200-201.	1.9	10
351	Mechanism of action of recombinant factor VIIa. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1138-1139.	1.9	98
352	Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2175-2178.	1.9	26
353	Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2368-2373.	1.9	70
354	Recombinant factor VIIa in orthotopic liver transplantation. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 169-174.	0.5	37
355	Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 557-562.	0.5	28
356	Recombinant factor VIIa enhances deposition of platelets with congenital or acquired $\beta_3$ deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. <i>Blood</i> , 2003, 101, 1864-1870.	0.6	107
357	Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 169-74.	0.5	12
358	Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. <i>Blood</i> , 2002, 99, 175-179.	0.6	159
359	Haemostatic abnormalities in patients with liver disease. <i>Journal of Hepatology</i> , 2002, 37, 280-287.	1.8	212
360	Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. <i>Hepatology</i> , 2002, 35, 616-621.	3.6	68

#	ARTICLE	IF	CITATIONS
361	Thrombin-Activatable Fibrinolysis Inhibitor Deficiency in Cirrhosis Is Not Associated With Increased Plasma Fibrinolysis. <i>Gastroenterology</i> , 2001, 121, 131-139.	0.6	264
362	The Defective Down Regulation of Fibrinolysis in Haemophilia A Can Be Restored by Increasing the TAFI Plasma Concentration. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1035-1039.	1.8	125
363	The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1035-9.	1.8	25
364	Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. <i>Thrombosis and Haemostasis</i> , 1999, 81, 87-95.	1.8	11
365	Anticoagulation in thrombocytopenic patients â€” time to rethink?. <i>Journal of Thrombosis and Haemostasis</i> , 0, , .	1.9	2